Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Company

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced that, due to safety findings in the ongoing Phase 2 clinical trials, it has discontinued the RIST4721 development program in order to protect patient safety. read more →

Aristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs Progress

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the appointments of three experienced drug development experts to key positions as it works to progress and expand its clinical pipeline: Himanshu Patel, D.O., as Executive Medical Director, Jennifer Barnes, Ph.D., as Senior Director, Clinical Science, and Walter Frank Eng, PharmD, as Associate Director, Clinical Science. read more →

Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS), a chronic and progressive inflammatory dermatological condition. read more →

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the appointment of Mark Gergen and Daniel O'Connell, M.D., Ph.D., to the Board of Directors. Mr. Gergen will take an independent board seat, and Dr. O'Connell will take a seat on behalf of Novo Holdings. The company also announced that Michael S. Vincent, M.D., Ph.D., will join the Aristea Therapeutics Board as a Board Observer on behalf of Pfizer Inc. read more →

Aristea Therapeutics

Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced it has dosed its first subject in the open-label extension (OLE) for its Phase 2b trial of RIST4721 in palmoplantar pustulosis (PPP), a rare dermatological condition. read more →

Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

SAN DIEGO, March 28, 2022 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of palmoplantar pustulosis (PPP), a rare inflammatory skin disorder. read more →

Aristea Therapeutics Announces Key Leadership Appointments to Advance its Clinical Pipeline

SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of Ciara Kennedy as Aristea Therapeutics' Chair of the Board of Directors and Fabio Magrini as Executive Medical Director. read more →

Aristea Therapeutics to Present at Biotech Showcase 2022 and H.C. Wainwright Bioconnect Conferences

SAN DIEGO, Jan. 6, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate virtually in the following investor conferences in January: read more →

Aristea Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October: read more →

Aristea Appoints Justin Thacker as Chief Financial Officer

SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare and serious inflammatory diseases, today announced the appointment of Justin Thacker, CPA, as Chief Financial Office read more →

Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

Business Wire, San Diego – July, 27 2021 –Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. read more →

Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases

PR Newswire, San Diego – July 27, 2021 – Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing. Led by Fidelity Management & Research Company, LLC., the financing included participation by existing investor Novo Holdings A/S and new investors Arena Pharmaceuticals and funds managed by Tekla Capital Management, LLC. read more →

Aristea Therapeutics to Present at the 2nd Annual LifeSci Partners Private Company Virtual Summer Symposium

SAN DIEGO, July 16, 2021 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced that it will present at the 2nd Annual LifeSci Partners Private Company Summer Symposium. James Mackay, Ph.D., Chief Executive Officer of Aristea Therapeutics, will provide an overview of the company's clinical programs, including its lead product candidate RIST4721, an oral CXCR2 antagonist being developed for the treatment of Palmoplantar pustulosis (PPP) with potential across a range of neutrophil-mediated diseases. RIST4721 has completed Phase 2a and it is on track to initiate Phase 2b this year. read more →

Aristea Therapeutics Announces the Completion of Enrollment in RIST4721-201, a Phase 2a Proof-of-Concept Study of RIST4721 for the treatment of Palmoplantar Pustulosis (PPP)

PR Newswire, San Diego – October 16, 2019 – Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has completed enrollment in RIST4721-201, a Phase 2a study to evaluate the efficacy and safety of RIST4721 in patients with palmoplantar pustulosis. read more →

Aristea Therapeutics to Present at the 2019 BIO Investor Forum

SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that the Company will present at the 2019 BIO Investor Forum being held October 22-23, 2019 in San Francisco, CA. Dr. James Mackay, President and CEO of Aristea, will present at the conference and meet with investors. read more →

Aristea Therapeutics Announces Formation of Scientific Advisory Board

PR Newswire, San Diego – September 12, 2019 – Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in inflammatory and dermatological disease drug development. The SAB will work closely with Aristea’s leadership to advance its lead therapeutic, RIST4721, for patients with palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States. The SAB will also assist the Aristea management team with the planned development of additional indications for RIST4721 and the expansion and subsequent development of the Aristea portfolio. read more →

Aristea Therapeutics Appoints Nihar Bhakta, M.D. as Chief Medical Officer

PR Newswire, San Diego – September 3, 2019 – Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the appointment of Nihar Bhakta, M.D. as Chief Medical Officer. In his new role, Dr. Bhakta will be responsible for leading and expanding Aristea’s clinical portfolio and will serve as a key member of its executive leadership team. read more →

Aristea Therapeutics Appoints Ciara Kennedy, Ph.D. to its Board of Directors

PR Newswire, San Diego – May 8, 2019 – Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the appointment of Ciara Kennedy, Ph.D. as an independent member of its Board of Directors. read more →

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has secured $15M from Novo Holdings A/S (Novo Holdings) in a completed Series A financing. Aristea has also obtained exclusive global rights to its lead program RIST4721, from AstraZeneca. Aristea plans to initiate a Phase 2 clinical study in early 2019. In connection with the financing, Tiba Aynechi, Ph.D and Ken Harrison, Ph.D from Novo Ventures (US), Inc have been appointed to Aristea’s Board of Directors. read more →